Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study

Figures & data

Figure 1 Efficacy of treatment with secukinumab in patients with moderate to severe psoriasis stratified by age < 65 years and ≥ 65 years. (A) PASI90 response rates during treatment. (B) Absolute PASI scores during treatment.

Table 1 Summary of TEAEs

Overall Analysis	Age < 65 Years		Age ≥ 65 Years		Total
	(N=397)		(N=36)		(N=433)
	n	%	n	%	n	%
Number of TEAEs	579	–	83	–	662	–
Number of patients with TEAEs	215	54.6	17	47.22	232	53.58
Number of patients with serious TEAEs	28	7.05	3	8.33	31	7.16
Number of patients with TEAEs related to study drug	69	17.38	7	19.44	76	17.55
Number of patients with TEAEs leading to discontinuation of study drug	27	6.80	3	8.33	30	6.93
Deaths	1	0.25	1	2.78	2	0.46

Abbreviation: TEAEs, treatment-emergent adverse events.